Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Strategic Alliance in Cervical Cancer Diagnostics

By Labmedica staff writers
Posted on 11 Apr 2001
A strategic alliance has been formed by Ampersand Medical Corp. More...
(Chicago, IL, USA; www.ampersandmedical.com) and AmeriPath, Inc. (Riviera Beach, FL, USA; www.ameripath.com) for the joint development of new diagnostic technologies and products relating to cervical cancer.

AmeriPath will receive an undisclosed amount of equity in Ampersand as compensation for its development work and will also provide laboratory services for continued research and clinical trials. Ampersand will pay Ameripath for these services. The two companies will work to bring to market several of Ampersand's products. These include its InPath In-Cell test for the human papillomavirus (HPV) through the identification of increased activity of the E6 and E7 oncogenes for HPV and its disposable liquid cell preservation and slide-preparation system that requires no instrumentation.

AmeriPath will purchase and distribute Ampersand's e2 Collector for cervical samples and will conduct a pilot project using Ampersand's Samba telemedicine and image-management system. AmeriPath is a leading U.S. provider of anatomic pathology, cancer diagnostics, and laboratory information services to doctors and hospitals. "AmeriPath will play a vital role in our goal to offer low cost/easy access cancer screening on a global basis,” said Peter P. Gombrich, chairman and CEO of Ampersand.



Related Links:
Ampersand
AmeriPath

Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Laboratory Software
ArtelWare
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.